The mortality benefit seen with the newer more potent oral P2Y(12) inhibitors prasugrel and ticagrelor over clopidogrel is dependent on the underlying risk: A class effect as suggested by a meta-regression analysis

Author(s):
Jukema, J.W. (0000-0002-3246-8359); Alber, H.; Widimsky, P.
Published
2018
Publication type
Article / Letter to editor
P2Y(12) inhibitorPrasugrelTicagrelorAcute coronary syndrome (ACS)Meta-regressionMortality
Date issued
2018-04-30
Language
English
Is part of
Cor et Vasa (2018), Vol. 60, no. 2, p. E127-E132
hdl
1887/94591
doi
10.1016/j.crvasa.2017.07.004